Skip to main content
Log in

Analysis of the Costs of NSAID-Associated Gastropathy

Experience in a US Health Maintenance Organisation

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

Clinicians recognise nonsteroidal anti-inflammatory drugs (NSAIDs) as valuable first-line agents in the treatment of rheumatic disorders and as dangerous irritants to the gastrointestinal tract. This has led to questions about the economic impact of NSAID-induced gastropathy in populations.

This study estimated the 1992 costs of NSAID-associated gastropathy episodes, and calculated an iatrogenic cost factor for NSAID-associated gastropathy among elderly members of a health maintenance organisation (HMO), the Northwest Region of Kaiser Permanente.

Using data retrieved from automated databases and from medical records, NSAID and antiulcer drug costs were calculated, and estimates were made of the incidence rates of inpatient and outpatient NSAID-associated gastropathies, the services provided to treat them, and the cost of those services.

Kaiser Permanente Northwest spent $US0.35 for each $US1.00 spent on NSAID therapy for the elderly, an iatrogenic cost factor of 1.35. The estimated average treatment per NSAID-associated gastropathy episode was $US2172. The average outpatient pharmacy cost per elderly NSAID user was $US80 and estimated average NSAID-associated treatment cost per elderly NSAID user was $US43.

Although the findings were specific to the HMO because of the databases used, the methodology employed and the drug formulary influence on NSAID selection, they show that a substantial amount of resources were used to treat NSAID-induced gastropathies in the elderly, underscoring the risk of prescribing NSAIDs and reinforcing the need for their prudent use in elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Zeidler H. Epidemiology and economics of NSAID-induced gastropathy. Scand J Rheumatol 1992; 21 Suppl. 92: 3–8

    Article  Google Scholar 

  2. Baum C, Kennedy DL, Forbes MB. Utilization of anti-inflammatory drugs. Arthritis Rheum 1985; 28: 686–92

    Article  PubMed  CAS  Google Scholar 

  3. Graham DY. Prevention of gastroduodenal injury induced by chronic nonsteroidal anti-inflammatory drug therapy. Gastroenterology 1989; 96: 675–81

    PubMed  CAS  Google Scholar 

  4. Bradley JD, Brandt KD, Katz BP, et al. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991; 325: 87–91

    Article  PubMed  CAS  Google Scholar 

  5. Bradley JD, Brandt KD, Kalasinski LA, et al. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic. J Rheumatol 1992; 19: 1950–4

    PubMed  CAS  Google Scholar 

  6. Parr G, Darekar B, Fletcher A, et al. Joint pain and the quality of life; results of a randomized trial. Br J Clin Pharmacol 1989; 27: 235–42

    Article  PubMed  CAS  Google Scholar 

  7. Beard K, Walker AM, Perera DR, et al. Nonsteroidal anti-inflammatory drugs and hospitalization for gastroesophageal bleeding in the elderly. Arch Intern Med 1987; 147: 1621–3

    Article  PubMed  CAS  Google Scholar 

  8. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 787–96

    PubMed  CAS  Google Scholar 

  9. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109: 359–63

    PubMed  CAS  Google Scholar 

  10. Henry D, Lim LL-Y, Rodriguez LAG, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative metaanalysis. BMJ 1996; 313: 1563–6

    Article  Google Scholar 

  11. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 1989; 149: 2061–5

    Article  PubMed  CAS  Google Scholar 

  12. Knill-Jones RP. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville. Scand J Rheumatol 1992; 21 Suppl. 96: 59–62

    Article  Google Scholar 

  13. Carrin GJ, Torfs KE. Economic evaluation of prophylactic treatment with misoprostol in osteoarthritic patients treated with NSAIDs: the case of Belgium. Rev Epidemiol Sante Publique 1990; 38: 187–99

    PubMed  CAS  Google Scholar 

  14. de Pouvourville G. The economic consequences of NSAID-induced gastropathy: the French context. Scand J Rheumatol 1992; 21 Suppl. 96: 49–53

    Article  Google Scholar 

  15. de Pouvourville G, Bader JP. Cost-effectiveness of preventive treatment with misoprostol in NSAID-related gastric ulcers. Gastroenterol Clin Biol 1991; 15: 399–404

    PubMed  Google Scholar 

  16. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988; 88 Suppl. 2A: 20–4

    Article  Google Scholar 

  17. Hochberg MC. Association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal disease: epidemiologic and economic considerations. J Rheumatol 1992; 19 Suppl. 36: 63–7

    Google Scholar 

  18. Kolodny AL, Klipper A. Final report on the cost of treating arthritic disease: comparison between salicylates and non-salicylate nonsteroidal anti-inflammatory drugs. Semin Arthritis Rheum 1985; 14 Suppl. 1: 20–4

    Article  PubMed  CAS  Google Scholar 

  19. Loeb DS, Ahlquist DA, Talley NJ. Management of gastroduodenopathy associated with use of nonsteroidal antiinflammatory drugs. Mayo Clin Proc 1992; 67: 354–64

    PubMed  CAS  Google Scholar 

  20. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. Arch Intern Med 1996; 156: 1530–6

    Article  PubMed  CAS  Google Scholar 

  21. Stucki G, Johannesson M, Liang MH. Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with arthritis? A review of conflicting economic evaluations. Arch Intern Med 1994; 154: 2020–5

    Article  PubMed  CAS  Google Scholar 

  22. de Pouvourville G, Tasch RF. The economic consequences of NSAID-induced gastrointestinal damage. Eur J Rheumatol Inflamm 1993; 13: 33–40

    PubMed  Google Scholar 

  23. Gabriel SE, Campion ME, O’Fallon WM. A cost-utility of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1994; 37: 331–41

    Google Scholar 

  24. Hsiao WC, Couch N, Causino N, et al. Resource-based relative values. JAMA 1988; 260: 2347–53

    Article  PubMed  CAS  Google Scholar 

  25. Penn RL, Johnson RE, Vogt TM. How the CHR RVS was developed, and analysis of the cost of production of RVS units in KP. Portland (OR): Center for Health Research, Kaiser Permanente, 1983

    Google Scholar 

  26. US Bureau of the Census. Statistical abstract of the United States. 115th ed. Washington, DC: US Bureau of the Census, 1995: 494

    Google Scholar 

  27. US Bureau of the Census. Statistical abstract of the United States. 114th ed. Washington, DC: US Bureau of the Census, 1994: 435

    Google Scholar 

  28. Hornbrook MC, Goodman MJ. Assessing relative health plan risk with the RAND-36 health survey. Inquiry 1995; 32: 56–74

    PubMed  CAS  Google Scholar 

  29. Fries JF, Spitz PW, Williams CA, et al. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum 1990; 33: 121–30

    Article  PubMed  CAS  Google Scholar 

  30. Fries JF, Williams CA, Bloch DA. The relative toxicity of non-steroidal anti-inflammatory drugs. Arthritis Rheum 1991; 34: 1353–60

    Article  PubMed  CAS  Google Scholar 

  31. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257–63

    PubMed  CAS  Google Scholar 

  32. Skeith KJ, Wright M, Davis P. Differences in NSAID tolerability profiles — fact or fiction? Drug Saf 1994; 10: 183–95

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johnson, R.E., Hornbrook, M.C., Hooker, R.S. et al. Analysis of the Costs of NSAID-Associated Gastropathy. Pharmacoeconomics 12, 76–88 (1997). https://doi.org/10.2165/00019053-199712010-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199712010-00008

Keywords

Navigation